EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Open Access

Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment

Macarena Hernández-Jiménez, Francisco Abad-Santos, Ian Cotgreave, Jaime Gallego, Bernd Jilma, Alan Flores, Tudor G Jovin, José Vivancos, María Hernández-Pérez, Carlos A Molina, Joan Montaner, Joaquín Casariego und 22 weitere

JAMA Neurology · 01.08.2023 · 80 (8) · 779

DOI: 10.1001/jamaneurol.2023.1660 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Neurology, erschienen am 01.08.2023. Verfasst von Macarena Hernández-Jiménez und 33 weiteren Autor:innen. Beteiligte Einrichtung: aptaTargets, Madrid, Spain. Hauptthemen laut MEDLINE: Ischemic Stroke, Brain Ischemia, Stroke, Endovascular Procedures. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance ApTOLL is a TLR4 antagonist with proven preclinical neuroprotective effect and a safe profile in healthy volunteers.

Objective

To assess the safety and efficacy of ApTOLL in combination with endovascular treatment (EVT) for patients with ischemic stroke. Design, Setting, and Participants This phase 1b/2a, double-blind, randomized, placebo-controlled study was conducted at 15 sites in Spain and France from 2020 to 2022. Participants included patients aged 18 to 90 years who had ischemic stroke due to large vessel occlusion and were seen within 6 hours after stroke onset; other criteria were an Alberta Stroke Program Early CT Score of 6 to 10, estimated infarct core volume on baseline computed tomography perfusion of 5 to 70 mL, and the intention to undergo EVT. During the study period, 4174 patients underwent EVT.

Interventions

In phase 1b, 0.025, 0.05, 0.1, or 0.2 mg/kg of ApTOLL or placebo; in phase 2a, 0.05 or 0.2 mg/kg of ApTOLL or placebo; and in both phases, treatment with EVT and intravenous thrombolysis if indicated. Main Outcomes and Measures The primary end point was the safety of ApTOLL based on death, symptomatic intracranial hemorrhage (sICH), malignant stroke, and recurrent stroke. Secondary efficacy end points included final infarct volume (via MRI at 72 hours), NIHSS score at 72 hours, and disability at 90 days (modified Rankin Scale [mRS] score).

Results

In phase Ib, 32 patients were allocated evenly to the 4 dose groups. After phase 1b was completed with no safety concerns, 2 doses were selected for phase 2a; these 119 patients were randomized to receive ApTOLL, 0.05 mg/kg (n = 36); ApTOLL, 0.2 mg/kg (n = 36), or placebo (n = 47) in a 1:1:√2 ratio. The pooled population of 139 patients had a mean (SD) age of 70 (12) years, 81 patients (58%) were male, and 58 (42%) were female. The primary end point occurred in 16 of 55 patients (29%) receiving placebo (10 deaths [18.2%], 4 sICH [7.3%], 4 malignant strokes [7.3%], and 2 recurrent strokes [3.6%]); in 15 of 42 patients (36%) receiving ApTOLL, 0.05 mg/kg (11 deaths [26.2%], 3 sICH [7.2%], 2 malignant strokes [4.8%], and 2 recurrent strokes [4.8%]); and in 6 of 42 patients (14%) receiving ApTOLL, 0.2 mg/kg (2 deaths [4.8%], 2 sICH [4.8%], and 3 recurrent strokes [7.1%]). ApTOLL, 0.2 mg/kg, was associated with lower NIHSS score at 72 hours (mean difference log-transformed vs placebo, −45%; 95% CI, −67% to −10%), smaller final infarct volume (mean difference log-transformed vs placebo, −42%; 95% CI, −66% to 1%), and lower degrees of disability at 90 days (common odds ratio for a better outcome vs placebo, 2.44; 95% CI, 1.76 to 5.00). Conclusions and Relevance In acute ischemic stroke, 0.2 mg/kg of ApTOLL administered within 6 hours of onset in combination with EVT was safe and associated with a potential meaningful clinical effect, reducing mortality and disability at 90 days compared with placebo. These preliminary findings await confirmation from larger pivotal trials. Trial Registration ClinicalTrials.gov Identifier: NCT04734548

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ischemic StrokeBrain IschemiaStrokeEndovascular ProceduresHumansMaleFemaleTreatment OutcomeCerebral InfarctionIntracranial HemorrhagesThrombectomy

Autor:innen und Institutionen

  • aptaTargets, Madrid, Spain.
  • Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Chemical and Pharmaceutical Safety, Division of Bioeconomy and Health, Research Institutes of Sweden, Södertälje, Sweden.
  • Neurological Center of Navarra, Navarra, Spain.
  • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Zitieren

APA

Hernández-Jiménez, M., Abad-Santos, F., Cotgreave, I., Gallego, J., Jilma, B., Flores, A., Jovin, T. G., Vivancos, J., Hernández-Pérez, M., Molina, C. A., Montaner, J., Casariego, J., Dalsgaard, M., Liebeskind, D. S., Cobo, E., Castellanos, M., Portela, P. C., Masjuán, J., Moniche, F., …, & Ribo, M. (2023). Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment. JAMA Neurology, 80(8), 779. https://doi.org/10.1001/jamaneurol.2023.1660

Vancouver

Hernández-Jiménez M, Abad-Santos F, Cotgreave I, Gallego J, Jilma B, Flores A, et al. Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment. JAMA Neurology. 2023;80(8):779. doi:10.1001/jamaneurol.2023.1660

BibTeX
@article{HernndezJimnez2023,
  author = {Hernández-Jiménez, Macarena and Abad-Santos, Francisco and Cotgreave, Ian and Gallego, Jaime and Jilma, Bernd and Flores, Alan and Jovin, Tudor G and Vivancos, José and Hernández-Pérez, María and Molina, Carlos A and Montaner, Joan and Casariego, Joaquín and Dalsgaard, Mads and Liebeskind, David S and Cobo, Erik and Castellanos, Mar and Portela, Pere Cardona and Masjuán, Jaime and Moniche, Francisco and Tembl, José Ignacio and Terceño Izaga, Mikel and Arenillas, Juan F and Callejas, Patricia and Olivot, Jean Marc and Calviere, Lionel and Henon, Hilde and Mazighi, Mikael and Piñeiro, David and Pugliese, Marco and González, Victor M and Moro, Maria Angeles and Garcia-Tornel, Alvaro and Lizasoain, Ignacio and Ribo, Marc},
  title = {Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment},
  journal = {JAMA Neurology},
  year = {2023},
  volume = {80},
  number = {8},
  pages = {779},
  doi = {10.1001/jamaneurol.2023.1660}
}
Kostenlos starten →